Biosimilars: still a work in progress

Evidence is pointing to most pharmacists still struggling to come to grips with their role in providing biosimilar medicines It’s now been seven years since the Pharmaceutical Benefits Advisory Committee (PBAC) made the decision to consider the marking as equivalent—or “a” flagging—of biosimilar medicines and their reference products, allowing pharmacists to substitute biosimilars for originator